eXIthera Pharmaceuticals Overview
- Year Founded
-
2012
- Status
-
Acquired/Merged
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$201K
eXIthera Pharmaceuticals General Information
Description
Developer of novel, potent, and selective small molecule inhibitors designed to prevent thrombosis with limited risk for bleeding side effects and without the need for a reversal agent. The company focuses on developing stroke prevention and anti-thrombosis drugs that have a pathophysiological role in the initiation of intravascular thrombi without causing undue bleeding, enabling physicians to treat the serious consequences of venous thromboembolism, deep vein thrombosis, stroke, and heart attack.
Contact Information
Website
www.exithera.comCorporate Office
- 1900 West Park Drive
- Suite 280
- Westborough, MA 01581
- United States
Corporate Office
- 1900 West Park Drive
- Suite 280
- Westborough, MA 01581
- United States
eXIthera Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Merger/Acquisition | 15-Sep-2025 | $201K | Completed | Clinical Trials - Phase 1 | ||
| 5. Later Stage VC | 01-Jul-2022 | Completed | Clinical Trials - Phase 1 | |||
| 4. Later Stage VC | 01-Apr-2019 | Completed | Clinical Trials - Phase 1 | |||
| 3. Later Stage VC (Series B) | 24-Aug-2017 | Completed | Clinical Trials - Phase 1 | |||
| 2. Early Stage VC (Series B) | 16-May-2016 | $10M | $14M | Completed | Clinical Trials - Phase 1 | |
| 1. Early Stage VC (Series A) | 01-Jan-2013 | $4M | $4M | Completed | Clinical Trials - Phase 1 |
eXIthera Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A |
eXIthera Pharmaceuticals Patents
eXIthera Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2023185852-A1 | Pharmaceutical composition for injection comprising cyclic lactam compound and method for preparing same | Inactive | 30-Mar-2022 | ||
| WO-2023185791-A1 | Preparation method for 2-aminopyridine derivative | Inactive | 28-Mar-2022 | ||
| AU-2021343468-A1 | Therapeutic compounds, compositions, and methods of use thereof | Inactive | 17-Sep-2020 | ||
| CA-3192119-A1 | Therapeutic compounds, compositions, and methods of use thereof | Pending | 17-Sep-2020 | ||
| EP-4213857-A1 | Therapeutic compounds, compositions, and methods of use thereof | Inactive | 17-Sep-2020 | A61K31/4427 |
eXIthera Pharmaceuticals Former Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Clal Biotechnology Industries | Venture Capital | Minority | ||
| Haisco Pharmaceutical Group Company | Corporation | Minority | ||
| Schooner Capital | Growth/Expansion | Minority |
eXIthera Pharmaceuticals FAQs
-
When was eXIthera Pharmaceuticals founded?
eXIthera Pharmaceuticals was founded in 2012.
-
Where is eXIthera Pharmaceuticals headquartered?
eXIthera Pharmaceuticals is headquartered in Westborough, MA.
-
What industry is eXIthera Pharmaceuticals in?
eXIthera Pharmaceuticals’s primary industry is Drug Discovery.
-
Is eXIthera Pharmaceuticals a private or public company?
eXIthera Pharmaceuticals is a Private company.
-
What is the current valuation of eXIthera Pharmaceuticals?
The current valuation of eXIthera Pharmaceuticals is .
-
What is eXIthera Pharmaceuticals’s current revenue?
The current revenue for eXIthera Pharmaceuticals is .
-
How much funding has eXIthera Pharmaceuticals raised over time?
eXIthera Pharmaceuticals has raised $28.2M.
-
Who are eXIthera Pharmaceuticals’s investors?
Clal Biotechnology Industries, Haisco Pharmaceutical Group Company, and Schooner Capital have invested in eXIthera Pharmaceuticals.
-
When was eXIthera Pharmaceuticals acquired?
eXIthera Pharmaceuticals was acquired on 15-Sep-2025.
-
Who acquired eXIthera Pharmaceuticals?
eXIthera Pharmaceuticals was acquired by Cadrenal Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process